Immunovant, Inc. (IMVT) Stock Analysis
Catalyst-Driven edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $27.34: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Elevated put/call ratio: 28.88; Below-average business quality.
Immunovant is a clinical-stage immunology company developing IMVT-1402 (FcRn inhibitor) for IgG-mediated autoimmune diseases, with ongoing potentially registrational trials in Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP, and cutaneous lupus.... Read more
Sell if holding. Engine safety override at $27.34: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Elevated put/call ratio: 28.88; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.8/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 28d clear, semi cycle peak clear). Fails on weak momentum. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.0% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $27.34: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.8/10 and A.R:R 2.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 22%; Elevated put/call ratio: 28.88; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $25.46. Score 4.8/10, moderate confidence.
Take-profit target: $36.26 (+32.4% upside). Prior stop was $25.46. Stop-loss: $25.46.
Quality below floor (1.4 < 4.0).
Immunovant, Inc. trades at a P/E of N/A (forward -10.4). TrendMatrix value score: 9.0/10. Verdict: Sell.
24 analysts cover IMVT with a consensus score of 4.1/5. Average price target: $40.
What does Immunovant, Inc. do?Immunovant is a clinical-stage immunology company developing IMVT-1402 (FcRn inhibitor) for IgG-mediated autoimmune...
Immunovant is a clinical-stage immunology company developing IMVT-1402 (FcRn inhibitor) for IgG-mediated autoimmune diseases, with ongoing potentially registrational trials in Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP, and cutaneous lupus. No products approved; also developing batoclimab, which showed positive Phase 3 MG results.